Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Relapsed/Refractory DLBCL
NCT03576443Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Jul 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in diffuse large B-cell lymphoma (DLBCL), sponsored by Nordic Lymphoma Group. Primary endpoint: Overall Response Rate up to 112 weeks. Started Jul 2017; status: completed.
02
Drugs
idelalisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03576443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576443.